Spermidine
Human evidence and registered trials are visible in this field
14 human-evidence records · 0 active trials · 16,625 visible funding records · 4,084 universities
Longevity Patent Family
Application of N1-dihydrocaffeoyl-N10-caffeoyl spermidine in preparation of anti-aging drugs, health care products or functional food
Source-linked patent metadata for Application of N1-dihydrocaffeoyl-N10-caffeoyl spermidine in preparation of anti-aging drugs, health care products or functional food, including priority, record stage and longevity-topic connections.
Patent-family snapshot
Application publication visible
Family grouping brings related publications for the same invention together, instead of counting every national filing as a separate technology.
- Representative publication
- CN120392717A
- Earliest priority
- May 25, 2025
- Latest publication
- August 1, 2025
- Family publications
- 1
- Patent offices
- 1
Patent-to-Evidence Translation Map
What is happening in the same scientific field?
These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.
Organizations named in this family
Topics connected by metadata
Spermidine88% metadata match
What this family cites
- Earlier patent references
- 0
- Scientific and other non-patent references
- 0
- Priority dates represented
- 1
References show which earlier documents the patent record points to. They do not validate the invention or prove that cited research supports its claims.
How the patent office classifies this invention
No patent classification is available in the retained record.
Verify in the original patent source →